With narcolepsy trial win, Axsome looks to revive former Pfizer antidepressant on the US market
November 27, 2024Race is on for oral obesity drugs with multiple phase 3 trials vying for next-gen status in a $126B market
December 2, 2024FDA oncology advisory committee to weigh Exelixis’ Cabometyx in neuroendocrine tumors
zbecker
Wed, 11/27/2024 – 11:02
